OrsoBio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$67M
- Investors
-
8
OrsoBio General Information
Description
Operator of a clinical-stage biopharmaceutical company intended to develop therapies for organ dysfunction. The company develops therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemia, enabling patients to boost the energy metabolism of their bodies.
Contact Information
Website
www.orsobio.comCorporate Office
- 101 Jefferson Drive
- 1st Floor, Suite 124
- Menlo Park, CA 94025
- United States
Corporate Office
- 101 Jefferson Drive
- 1st Floor, Suite 124
- Menlo Park, CA 94025
- United States
OrsoBio Timeline
OrsoBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 28-Aug-2024 | $67M | Completed | Clinical Trials - Phase 2 | ||
| 3. Early Stage VC (Series A) | 07-Nov-2023 | Completed | Clinical Trials - Phase 2 | |||
| 2. Grant | 02-Nov-2022 | $2.3M | $15M | Completed | Clinical Trials - Phase 2 | |
| 1. Seed Round | 18-Mar-2022 | $15M | $15M | Completed | Clinical Trials - Phase 2 |
OrsoBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed-1 | 30,303,030 | $0.000010 | 8% | $0.33 | $0.33 | 1x | $0.33 | 6.96% |
| Seed | 20,000,000 | $0.000010 | 8% | $0.25 | $0.25 | 1x | $0.25 | 4.59% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
OrsoBio Comparisons
Industry
Financing
Details
OrsoBio Competitors (35)
One of OrsoBio’s 35 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Carmot Therapeutics | Formerly VC-backed | Berkeley, CA | ||||
| Altimmune | Corporate Backed or Acquired | Gaithersburg, MD | ||||
| Rivus Pharmaceuticals | Venture Capital-Backed | Charlottesville, VA | ||||
| Akero Therapeutics | Formerly VC-backed | South San Francisco, CA |
OrsoBio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
OrsoBio Patents
OrsoBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3104956-A1 | Novel lxr modulators with bicyclic core moiety | Active | 28-Jun-2018 | ||
| AU-2019293727-A1 | Novel lxr modulators with bicyclic core moiety | Active | 28-Jun-2018 | ||
| US-20210147398-A1 | Novel lxr modulators with bicyclic core moiety | Active | 28-Jun-2018 | ||
| US-11618747-B2 | Lxr modulators with bicyclic core moiety | Active | 28-Jun-2018 | ||
| AU-2019293727-B2 | Novel lxr modulators with bicyclic core moiety | Active | 28-Jun-2018 | C07D409/04 |
OrsoBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
OrsoBio Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ascenta Capital | Venture Capital | Minority | ||
| Woodline Partners | Hedge Fund | Minority | ||
| Eli Lilly and Company | Corporation | Minority | ||
| Enavate Sciences | Growth/Expansion | Minority | ||
| Longitude Capital | Venture Capital | Minority |
OrsoBio FAQs
-
When was OrsoBio founded?
OrsoBio was founded in 2020.
-
Where is OrsoBio headquartered?
OrsoBio is headquartered in Menlo Park, CA.
-
What is the size of OrsoBio?
OrsoBio has 15 total employees.
-
What industry is OrsoBio in?
OrsoBio’s primary industry is Biotechnology.
-
Is OrsoBio a private or public company?
OrsoBio is a Private company.
-
What is the current valuation of OrsoBio?
The current valuation of OrsoBio is .
-
What is OrsoBio’s current revenue?
The current revenue for OrsoBio is .
-
How much funding has OrsoBio raised over time?
OrsoBio has raised $167M.
-
Who are OrsoBio’s investors?
Ascenta Capital, Woodline Partners, Eli Lilly and Company, Enavate Sciences, and Longitude Capital are 5 of 8 investors who have invested in OrsoBio.
-
Who are OrsoBio’s competitors?
NGM Biopharmaceuticals, Carmot Therapeutics, Altimmune, Rivus Pharmaceuticals, and Akero Therapeutics are some of the 35 competitors of OrsoBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
